Abstract
Understanding the biological basis of clinical risk factors for severe COVID-19 is required to ensure at-risk patient populations receive appropriate clinical care. Patients with decompensated liver cirrhosis, in particular those classified as Childs-Pugh class B and C, are at increased risk of severe COVID-19 upon infection with SARS-CoV-2. The biological mechanisms underlying this are unknown. We hypothesised this may be due to changes in expression levels of intrinsic antiviral proteins within the serum as well as alterations in the innate immune response to SARS-CoV-2 infection. We identified significant alterations in the serum proteome of patients with more severe liver disease and an increased frequency of auto-antibodies capable of neutralising type I interferons. No difference in SARS-CoV-2 pseudoparticle infection or live SARS-CoV-2 virus infection was observed with serum from decompensated cirrhotic patients. Principal component analysis of the serum proteome identified two main clinical parameters associated with serum proteome changes – aetiology and MELD-Na score. Among patients with MELD-Na scores >20 we detected significant inhibition of IFN-α2b and IFN-α8 signalling but not IFN-β1a, mediated by auto-antibodies. Our results suggest pre-existing neutralising auto-antibodies targeting type I IFN may increase the likelihood of severe COVID-19 in chronic liver disease patients upon SARS-CoV-2 infection and may also be of relevance to other viral infections in this patient population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded through the partnership between Science Foundation Ireland and the Department for the Economy (Northern Ireland) under the SFI COVID-19 Rapid Response Call (20/COV/8362). The cohort recruitment was funded by the Health Research Board (EIA-2017-013). The SARS-CoV-2 nucleocapsid ELISA was a kind gift from Prof. Sean Doyle, Maynooth University, developed from Science Foundation Ireland (SFI) COVID-19 Rapid Response Funding (20/COV/0048). The SARS-CoV-2 anti-spike sero-assay work was funded by SFI Strategic Partnership Programme (20/SPP/3685).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received ethics approval from St Vincents Hospital Group Ethics Board as per the 1975 Declaration of Helsinki guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
